← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Octagen Corporation
Blue Bell, PA
$298,556
Total funding
9
Grants
Funding over time
peak $1M · FY2005–07$2M$1.5M$1M$500K$0
'05
'06
'07
Funding mix
By agency
NIH$298,556 · 9
By mechanism
R43$198,556 · 2
R41$100,000 · 1
R44$0 · 6
Investigators at Octagen Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Low Antigenicity Factor VIII$1,004,225
R44 · FY2006 · HL
Low Antigenicity Factor VIII$1,004,225
R44 · FY2005 · HL
Low Antigenicity Factor VIII$975,103
R44 · FY2007 · HL
Low Antigenicity Factor VIII$413,000
R44 · FY2002 · HL
Low Antigenicity Factor VIII$412,000
R44 · FY2001 · HL
Low Immunogenicity Factor VIII$100,000
R43 · FY2004 · HL
Gene Therapy for Hemophilia A$100,000
R41 · FY2002 · HL
LOW ANTIGENICITY FACTOR VIII$98,556
R43 · FY2000 · HL
OBI-1 - 304 Surgical study, acquired hemophilia$0
R44 · FY2005 · HL
OBl-1 301:Pivotal study, congential hemophilia, all bleeding categories$0
R44 · FY2005 · HL
OBI-1 - 302 Pivotal study, acquired hemophilia, all bleeding categories$0
R44 · FY2005 · HL
OBI-1 - 303 Surgical study, congenital hemophilia$0
R44 · FY2005 · HL
OBl-1 - 201: Dosing regimen, cogential hemophilia, non-life threatening bleeding$0
R44 · FY2005 · HL
OBI-1 - 305 Rescue theraphy, cong &acquired, all else failed$0
R44 · FY2005 · HL